Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AT-02 in Healthy Volunteers and Systemic Amyloidosis
NCT05521022Phase 1Recruiting
- Sponsor
- Attralus
- Start
- Sep 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AT-02 in systemic amyloidosis (4 arms), sponsored by Attralus. Primary endpoints: Treatment-Emergent Adverse Events, Dose-Limiting Toxicities up to 85 days and 2 more. Started Sep 2022; status: recruiting.
02
Drugs
AT-02
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT05521022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521022.